Navigation Links
Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2011
Date:1/26/2011

p>

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,400 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.Forward-Looking Statements

Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as TrueBeam and our radiographic flat panel detectors, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms "expect," "can," "could," "believe," "estimate," "outlook," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of economic conditions, including the strength of any recovery from the global recession; the impact of recently enacted federal health care legislation and any further health care reforms, and/o
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Inivata, a Cambridge, England -based ... the 2015 American Association for Cancer Research (AACR) Annual Meeting ... and a poster presentation. Michael Stocum , CEO ... nd . The presentation, entitled Monitoring the ... part of a session on Recent Advances in Diagnostics ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/dl9gbg/admetoxicology ) ... - Global Strategic Business Report" report to their ... for ADME-Toxicology Testing in US$ Million by the following ... The report provides separate comprehensive analytics for ... Japan , Europe , ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/vrd3bd/mammography ) has announced ... Strategic Business Report" report to their offering. ... Equipment in US$ Thousands by the following Product Segments: ... provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
Breaking Medicine Technology:Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization 2Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2
... Inc. (Nasdaq: TRBN ) today announced financial results ... 30, 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) , ... , Revenue for the third quarter and nine ... $12.8 million, respectively, compared with $3.8 million and $12.2 ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at ... on Wednesday, November 11, 2009 at 10:00 a.m. PT / ... finance and chief financial officer at Amylin Pharmaceuticals, will be ... presentation will be webcast and a recording will be made ...
Cached Medicine Technology:Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 2Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 3Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 4Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 5Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 6Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results 7
(Date:4/17/2015)... 18, 2015 Rosetta Radiology is proud ... out their list of diagnostic imaging services. This solidifies ... on the Upper East Side of Manhattan. , The ... capacity. The addition of PET-CT, combined with Rosetta’s state ... ability to work with patients through several stages of ...
(Date:4/17/2015)... 17, 2015 Alcohol and Violence , ... notes that drinking and driving has been the focus ... same time, the link between alcohol and crime received ... and violence and sexual assault, and their relationship to ... NCADD, 5.3 million adults in America were drinking alcohol ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 From the day ... ago, the Texas non-profit organization has empowered young people to ... effort to bring fresh water and the Gospel to ... Liberty University. Between March 17 and 27, students, faculty and ... 7,000 Liberians with fresh water and the Good News of ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Representatives Jim ... Diagnoses and Treatment Act HR 1849 in congress on ... rates and treatment for patients with the genetic disease. ... the past, would be the first to create a ... appropriate treatment of hereditary hemorrhagic telangiectasia. This would effectively ...
(Date:4/17/2015)... California (PRWEB) April 17, 2015 At ... Entertainment’s EcoLuxe Lounge and the “Salute to the Oscars” ... luxurious Beverly Hilton Hotel, overlooking the impressive Los Angeles ... were organized by Debbie Durkin, LA’s leading producer of ... Showcasing many of the world’s premier providers of eco-friendly ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2
... Calif., Feb. 12 The Centers for Disease ... heart disease is America,s leading cause of death. ... a new heart-related coronary attack, and about 470,000 ... American Heart Month, thousands of people nationwide focus ...
... West Pharmaceutical Services, Inc. (NYSE: WST ... quarter financial results before the market opens on Thursday, ... call to discuss the results and business expectations at ... please dial (888)790-3758 or (210)839-8398. The passcode is WST.A ...
... results -LAVAL, QC, Feb. 12 /PRNewswire-FirstCall/ - Labopharm Inc. ... that it will host a conference call on Thursday, ... fourth quarter 2008 financial results. Labopharm will report its ... approximately 7:00 a.m. the same day. , To access ...
... Health Coordinates North Benin Screening , ... Cotonou, Benin, ... hospital ship, the Africa Mercy, docked in Cotounou, Benin , ... nation,s Ministry of Health. , , , , ,The hospital ...
... referred to as ,male menopause, may not be a ... depression, it is estimated that four out of five ... Since 1999, re NEW MAN (renewman.com) has been renowned ... self administered testosterone and HGH (human growth hormone) treatments. ...
... Portola to Receive $75 Million Upfront Cash ... Plus Royalties on Future Sales --SOUTH SAN ... Inc., a privately-held biopharmaceutical company developing innovative ... disease, inflammatory disease and cancer, today announced ...
Cached Medicine News:Health News:The ISSA Offers 8 Tips for American Heart Month 2Health News:West to Host 2008 Fourth Quarter Conference Call 2Health News:Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET) 2Health News:Mercy Ship Arrives in Benin 2Health News:Mercy Ship Arrives in Benin 3Health News:Male Hormone Replacement Therapy Optimism for 2009 2Health News:Male Hormone Replacement Therapy Optimism for 2009 3Health News:Male Hormone Replacement Therapy Optimism for 2009 4Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 2Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 3
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
Medicine Products: